NasdaqGS:RXRXBiotechs
A Look At Recursion Pharmaceuticals (RXRX) Valuation After New AI Bioengineering Market Study
Precedence Research has released a broad study on AI-driven bioengineering that spotlights Recursion Pharmaceuticals (RXRX) for its AI biology and phenomics platform, highlighting high-throughput drug discovery and growing government funding across the sector.
See our latest analysis for Recursion Pharmaceuticals.
Despite the attention around AI-driven drug discovery and growing government support for bioengineering, Recursion Pharmaceuticals’ recent share price performance has been weak. The...